Disease · MONDO_0005582

binge eating disorder

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. binge eating disorder. Diseases, record MONDO_0005582. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005582

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: binge eating disorder; Open Targets
Open Targets ID: MONDO_0005582; Open Targets
Other names: binge eating; Open Targets
MeSH: D002032; MeSH
NCI Thesaurus: C97162; NCI Thesaurus
Highest stage of its drugs: Approval, for 1 of its 21 drugs, from DailyMed; Open Targets

Drugs21

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LISDEXAMFETAMINE DIMESYLATE	CHEMBL1201178	Small molecule	Approval	DailyMed	3	2	2	Drugs and targets
TOPIRAMATE	CHEMBL220492	Small molecule	Phase 3	ClinicalTrials.gov	4	4	4	Drugs and targets
SIBUTRAMINE	CHEMBL1419	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
SOLRIAMFETOL	CHEMBL4297620	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
ARMODAFINIL	CHEMBL1201192	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LIRAGLUTIDE	CHEMBL4084119	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RIMONABANT	CHEMBL111	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ZONISAMIDE	CHEMBL750	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
BUPROPION	CHEMBL894	Small molecule	Phase 2/3	ClinicalTrials.gov	6	6	6	Drugs and targets
NALTREXONE	CHEMBL19019	Small molecule	Phase 2/3	ClinicalTrials.gov	5	5	5	Drugs and targets

1 to 10 of 21

See all 21 drugs

Targets54

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SLC6A2	Monoamine transporter	7	Monoamine transporter inhibitor; Norepinephrine transporter inhibitor; Norepinephrine transporter releasing agent; Sodium-dependent noradrenaline transporter releasing agent	Approval	https://conductscience.org/library/genes/6530	Drugs and targets
SLC6A3	Monoamine transporter	7	Dopamine transporter inhibitor; Dopamine transporter releasing agent; Monoamine transporter inhibitor; Sodium-dependent dopamine transporter releasing agent	Approval	https://conductscience.org/library/genes/6531	Drugs and targets
SLC6A4	Monoamine transporter	3	Monoamine transporter inhibitor; Sodium-dependent serotonin transporter releasing agent	Phase 3	https://conductscience.org/library/genes/6532	Drugs and targets
GLP1R	Glucagon-like peptide 1 receptor	2	Glucagon-like peptide 1 receptor agonist	Phase 3	https://conductscience.org/library/genes/2740	Drugs and targets
OPRM1	Mu-type opioid receptor	2	Mu opioid receptor antagonist; Opioid receptors; mu/kappa/delta antagonist	Phase 2/3	https://conductscience.org/library/genes/4988	Drugs and targets
SCN10A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6336	Drugs and targets
SCN11A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/11280	Drugs and targets
SCN1A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6323	Drugs and targets
SCN2A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6326	Drugs and targets
SCN3A	Sodium channel alpha subunit	2	Sodium channel alpha subunit blocker	Phase 3	https://conductscience.org/library/genes/6328	Drugs and targets

1 to 10 of 54

See all 54 targets

Trials30

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00829283	Treatment of Obesity and Binge Eating: Behavioral Weight Loss Versus Stepped Care	Not applicable	191	2016-02-01	Obesity, Binge Eating	ORLISTAT, SIBUTRAMINE	Its record names the disease	ClinicalTrials.gov
NCT05113953	A Trial of Centanafadine Efficacy, Safety, and Tolerability in Adult Subjects With Binge Eating Disorder	Phase 2	147	2025-09-09	Binge-Eating Disorder	CENTANAFADINE	Its record names the disease	ClinicalTrials.gov
NCT03045341	Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Acute Treatment	Phase 2/3	136	2022-12-20	Binge-eating Disorder, Obesity	BUPROPION, NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT03047005	Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Maintenance Therapy	Phase 2/3	68	2023-05-06	Binge-Eating Disorder, Obesity	BUPROPION, NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT00414167	Craving, Binge Eating and Obesity	Phase 2/3	61	2014-03-28	Binge Eating Disorder, Obesity	BUPROPION	Its record names the disease	ClinicalTrials.gov
NCT03279731	Binge Eating Liraglutide Intervention	Phase 3	36	2020-11-24	Binge-Eating Disorder	LIRAGLUTIDE	Its record names the disease	ClinicalTrials.gov
NCT03063606	Behavioral and Pharmacologic Treatment of Binge Eating and Obesity: Specialist Treatment	Phase 2/3	31	2023-07-07	Binge-Eating Disorder, Obesity	BUPROPION, NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT02317744	Treatment of Binge Eating Disorder in Obesity: Naltrexone/ Bupropion Combination Versus Placebo	Not applicable	22	2017-12-22	Binge Eating Disorder	BUPROPION, NALTREXONE	Its record names the disease	ClinicalTrials.gov
NCT00601354	Adding Guided Self-Help Group Therapy to the Alli Weight Loss Program in Treating Binge Eating Disorder	Not applicable	17	2013-09-09	Overweight, Eating Disorders	ORLISTAT	Its record names the disease	ClinicalTrials.gov
NCT04278755	Binge Eating & Birth Control	Phase 2	8	2022-07-26	Bulimia Nervosa, Binge Eating, Eating Disorders, Binge-Eating Disorder	DROSPIRENONE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 30

See all 30 trials

Comparisons in its trials18

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Stepped-care vs Standard Care: Number of Subjects Who Reached Binge Eating Remission	65 of 152	16 of 39	191	NCT00829283	Trial comparisons
Stepped-care vs Standard Care: serious adverse events	0 of 152	0 of 39	191	NCT00829283	Trial comparisons
NB Medication vs Placebo: deaths from any cause	0 of 32	0 of 34	66	NCT03047005	Trial comparisons
NB Medication vs Placebo: serious adverse events	0 of 32	0 of 34	66	NCT03047005	Trial comparisons
Bupropion vs Placebo: serious adverse events	0 of 31	0 of 30	61	NCT00414167	Trial comparisons
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml vs Placebo: deaths from any cause	0 of 19	0 of 17	36	NCT03279731	Trial comparisons
Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml vs Placebo: serious adverse events	2 of 19	1 of 17	36	NCT03279731	Trial comparisons
On-going Blinded Pharmacotherapy (NB) vs On-going Blinded Pharmacotherapy (Placebo): deaths from any cause	0 of 15	0 of 16	31	NCT03063606	Trial comparisons
On-going Blinded Pharmacotherapy (NB) vs On-going Blinded Pharmacotherapy (Placebo): serious adverse events	0 of 15	0 of 16	31	NCT03063606	Trial comparisons
Naltrexone/ Bupropion Combination vs Pill Placebo: deaths from any cause	0 of 11	0 of 8	19	NCT02317744	Trial comparisons

1 to 10 of 18

See all 18 comparisons in its trials

Papers from its trials14

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
21151016	RESULT	1	PubMed
20948512	RESULT	1	PubMed
17194267	RESULT	1	PubMed
38321617	DERIVED	1	PubMed
36285406	DERIVED	1	PubMed
33218742	DERIVED	1	PubMed
32985114	DERIVED	1	PubMed
30013815	DERIVED	1	PubMed
26011779	DERIVED	1	PubMed
23656848	DERIVED	1	PubMed

1 to 10 of 14

See all 14 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005582

GET https://conductscience.org/api/diseases/v1/MONDO_0005582/drugs?page=2

API reference For AI assistants